The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities (Q38161874)

30 August 2017

title

The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities (English)

1 reference

head and neck squamous cell carcinoma

30 August 2017

main subject

1 reference

1 reference

Monika E Freiser

1

1 reference

30 August 2017

Paolo Serafini

series ordinal

2

1 reference

30 August 2017

Donald T Weed

series ordinal

3

1 reference

30 August 2017

publication date

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

57

1 reference

30 August 2017

issue

1-3

1 reference

30 August 2017

page(s)

52-69

1 reference

Immune suppression in head and neck cancers: a review

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

The inhibitors of apoptosis (IAPs) as cancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Revisiting immune-based therapies for aggressive follicular cell-derived thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Solid cancers after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Aerodigestive cancers in HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Upper aerodigestive tract squamous cell carcinoma. The human immunodeficiency virus connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

The clinical implications of antitumor immunity in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Galectins as modulators of tumor progression in head and neck squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Oral cancer cell lines can use multiple ligands, including Fas-L, TRAIL and TNF-alpha, to induce apoptosis in Jurkat T cells: possible mechanisms for immune escape by head and neck cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Negative regulation of T-cell function by PD-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Activating and inhibitory receptors of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Origin and development of dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Cutaneous dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Prognostic significance of Langerhans cell infiltration in cancer of the larynx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Langerhans cells related to prognosis in patients with laryngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Expression of dendritic cell phenotypic antigens in cervical lymph nodes of patients with hypopharyngeal and laryngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Macrophage polarization in tumour progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Paracrine angiogenic loop between head-and-neck squamous-cell carcinomas and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Nitric oxide and the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Arginine metabolism: nitric oxide and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Increased protein nitrosylation in head and neck squamous cell carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumor skewing of CD34+ cell differentiation from a dendritic cell pathway into endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tregs and rethinking cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: prognostic impact may depend on type of treatment and stage of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

FOXP3 subcellular localization predicts recurrence in oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Subcellular localization of FOXP3 in human regulatory and nonregulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Immunotherapy in head and neck cancer: current practice and future possibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Cancer and the Complement Cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

GM-CSF-based cancer vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

GM-CSF-secreting melanoma vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Research controversies in management of oral mucositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Immunotherapy of head and neck cancer: current and future considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Editorial: PGE2-producing MDSC: a role in tumor progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Expression of prostaglandin E2 receptors in oral squamous cell carcinomas and growth inhibitory effects of an EP3 selective antagonist, ONO-AE3-240.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

VEGF is up-regulated by hypoxic stimulation and related to tumour angiogenesis and severity of disease in oral squamous cell carcinoma: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Ex vivo induction of multiple myeloma–specific cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Interleukin-6 and its receptor in cancer: implications for translational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Involvement of chemokine receptors in organ-specific metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Macrophage inflammatory protein (MIP)1alpha and MIP1beta differentially regulate release of inflammatory cytokines and generation of tumoricidal monocytes in malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Expression of CCL5 (RANTES) and CCR5 in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

CCL2 is a potent regulator of prostate cancer cell migration and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Smoothing T cell roads to the tumor: Chemokine post-translational regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Human papillomavirus and survival of patients with oropharyngeal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Genetic modification of T lymphocytes for adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Application of adoptive T-cell therapy using tumor antigen-specific T-cell receptor gene transfer for the treatment of human leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Ifosfamide in the Treatment of Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Recurrent oral cancer: current and emerging therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Using antibodies to target cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Adoptive-cell-transfer therapy for the treatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Immunotherapy for head and neck cancer patients: shifting the balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Induction of cytotoxic T lymphocytes primed with tumor RNA-loaded dendritic cells in esophageal squamous cell carcinoma: preliminary step for DC vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Synthetic peptide-based cancer vaccines: lessons learned and hurdles to overcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Lm-LLO-Based Immunotherapies and HPV-Associated Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors im

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Increased Prevalence of Dysplastic and Malignant Lip Lesions in Renal-Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Emerging human papillomavirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Vascular Endothelial Growth Factor (VEGF) and Microvessel Density in Squamous Cell Carcinomas of the Larynx: an Immunohistochemical Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12026-013-8462-3

Tumor-induced apoptosis of T cells: amplification by a mitochondrial cascade

21 January 2018

1 reference

12 December 2020

Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease

1 reference

12 December 2020

Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor

1 reference

12 December 2020

Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients.

1 reference

12 December 2020

The incidence of p53 mutations increases with progression of head and neck cancer

1 reference

12 December 2020

Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma

1 reference

12 December 2020

Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes

1 reference

12 December 2020

Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

1 reference

12 December 2020

Molecular mechanisms of treg-mediated T cell suppression

1 reference

12 December 2020

The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells

1 reference

12 December 2020

The decreased expression of CD3 ζ chains in cancer patients is not reversed BY IL-2 Administration

1 reference

12 December 2020

Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo

1 reference

12 December 2020

Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance

1 reference

12 December 2020

Clinical significance of defective dendritic cell differentiation in cancer

1 reference

12 December 2020

In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice

1 reference

12 December 2020

Dual role of VEGF family members in the pathogenesis of head and neck cancer (HNSCC): possible link between angiogenesis and immune tolerance.

1 reference

12 December 2020

The concept of immunological surveillance

1 reference

12 December 2020

Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells

1 reference

12 December 2020

P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells

1 reference

12 December 2020

Immunosuppression and the development of malignancies of the upper airway and related structures

1 reference

12 December 2020

Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy

1 reference

12 December 2020

Immunohistochemical study on overexpression of cyclooxygenase-2 in squamous cell carcinoma of the oral cavity: its importance as a prognostic predictor

1 reference

12 December 2020

COX-2 expression in dysplasia of the head and neck: correlation with elF4E

1 reference

12 December 2020

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx

1 reference

12 December 2020

Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.

1 reference

12 December 2020

CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer

1 reference

12 December 2020

Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer

1 reference

12 December 2020

Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis

1 reference

12 December 2020

Mast cell tryptase promotes breast cancer migration and invasion

1 reference

12 December 2020

Human natural killer cells: a comprehensive review.

1 reference

12 December 2020

CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers

1 reference

12 December 2020

Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck

1 reference

12 December 2020

Correlation of c-erbB-2 and S-100 expression with the malignancy grading and anatomical site in oral squamous cell carcinoma

1 reference

12 December 2020

Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells

1 reference

12 December 2020

Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

1 reference

12 December 2020

Skewed differentiation of bone marrow CD34+ cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3

1 reference

12 December 2020

Hypoxia inducible factor-alpha expression correlates with vascular endothelial growth factor-C expression and lymphangiogenesis/angiogenesis in oral squamous cell carcinoma

1 reference

12 December 2020

Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial

1 reference

12 December 2020

Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels

1 reference

12 December 2020

Fibrin deposition in squamous cell carcinomas of the larynx and hypopharynx

1 reference

12 December 2020

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers

1 reference

12 December 2020

Increased presence of CD34+ cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells

1 reference

12 December 2020

Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor

1 reference

12 December 2020

Preclinical models of HPV+ and HPV- HNSCC in mice: an immune clearance of HPV+ HNSCC

1 reference

12 December 2020

Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma

1 reference

12 December 2020

Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.

1 reference

12 December 2020

Prospects and limitations of T cell receptor gene therapy

1 reference

12 December 2020

Better understanding tumor-host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies

1 reference

12 December 2020

Secretion of tumor-promoting and immune suppressive cytokines by cell lines of head and neck squamous cell carcinoma

1 reference

12 December 2020

The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck

1 reference

12 December 2020

The pros and cons of chemokines in tumor immunology.

1 reference

12 December 2020

Immune alterations and immunotherapy prospects in head and neck cancer.

1 reference

12 December 2020

Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens.

1 reference

12 December 2020

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

1 reference

12 December 2020

Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer

1 reference

12 December 2020

Intensive recombinant interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma

1 reference

12 December 2020

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo

1 reference

12 December 2020

10.1007/S12026-013-8462-3

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1032718076

0 references

1 reference